There is increasing evidence that vitamin B6, given either as pyridoxine or pyridoxal 5′-phosphate, can sometimes result in improved seizure control in idiopathic epilepsy. Whole-exome sequencing was used to identify a de novo mutation (c.629G>A; p.Arg210His) in KCNQ2 in a 7-year-old patient whose neonatal seizures showed a response to pyridoxine and who had a high plasma to CSF pyridoxal 5′-phosphate ratio, usually indicative of an inborn error of vitamin B6 metabolism. This mutation has been described in three other patients with neonatal epileptic encephalopathy. A review of the literature was performed to assess the effectiveness of vitamin B6 treatment in patients with a KCNQ2 channelopathy. Twenty-three patients have been reported to have been trialled with B6; in three of which B6 treatment was used alone or in combination with other antiepileptic drugs to control seizures. The anticonvulsant effect of B6 vitamers may be propagated by multiple mechanisms including direct antagonist action on ion channels, antioxidant action on excess reactive oxygen species generated by increased neuronal firing and replenishing the pool of pyridoxal 5′-phosphate needed for the synthesis of some inhibitory neurotransmitters. Vitamin B6 may be a promising adjunctive treatment for patients with channelopathies and the wider epileptic population. This report also demonstrates that an abnormal plasma to CSF pyridoxal 5′-phosphate ratio may not be exclusive to inborn errors of vitamin B6 metabolism.
- Anticonvulsant Effect
- P2X7R Antagonist
- KCNQ2 Mutation
- Ohtahara Syndrome
- Benign Familial Neonatal Seizure
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Competing interests: None declared
Emma S. Reid and Hywel Williams contributed equally to the manuscript.
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Allen NM, Mannion M, Conroy J et al (2014) The variable phenotypes of KCNQ-related epilepsy. Epilepsia 55(9):e99–e105
Biervert C, Schroeder BC, Kubisch C et al (1998) A potassium channel mutation in neonatal human epilepsy. Science 279(5349):403–406
Chumnantana R, Yokochi N, Yagi T (2005) Vitamin B6 compounds prevent the death of yeast cells due to menadione, a reactive oxygen generator. Biochim Biophys Acta 1722(1):84–91
Footitt EJ, Heales SJ, Mills PB, Allen GF, Oppenheim M, Clayton PT (2011) Pyridoxal 5′-phosphate in cerebrospinal fluid; factors affecting concentration. J Inherit Metab Dis 34(2):529–538
Footitt EJ, Clayton PT, Mills K et al (2013) Measurement of plasma B6 vitamer profiles in children with inborn errors of vitamin B6 metabolism using an LC-MS/MS method. J Inherit Metab Dis 36(1):139–145
Guerin A, Aziz AS, Mutch C et al (2014) Pyridox(am)ine-5-phosphate oxidase deficiency treatable cause of neonatal epileptic encephalopathy with burst suppression: case report and review of the literature. J Child Neurol. doi:10.1177/0883073814550829
Henshall DC, Diaz-Hernandez M, Miras-Portugal MT, Engel T (2013) P2X receptors as targets for the treatment of status epilepticus. Front Cell Neurosci 7:237
Hunt AD, Stokes J, McCrory WW, Stroud HH (1954) Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics 13(2):140–145
Jimenez-Pacheco A, Mesuret G, Sanz-Rodriguez A et al (2013) Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079. Epilepsia 54(9):1551–1561
Kuki I, Takahashi Y, Okazaki S et al (2013) Vitamin B6-responsive epilepsy due to inherited GPI deficiency. Neurology 81(16):1467–1469
Mefford HC, Cook J, Gospe SM Jr (2012) Epilepsy due to 20q13.33 subtelomere deletion masquerading as pyridoxine-dependent epilepsy. Am J Med Genet A 158A(12):3190–3195
Midttun O, Hustad S, Solheim E, Schneede J, Ueland PM (2005) Multianalyte quantification of vitamin B6 and B2 species in the nanomolar range in human plasma by liquid chromatography-tandem mass spectrometry. Clin Chem 51(7):1206–1216
Mills PB, Footitt EJ, Mills KA et al (2010) Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 133(Pt 7):2148–2159
Mills PB, Camuzeaux SS, Footitt EJ et al (2014) Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain 137(Pt 5):1350–1360
Numis AL, Angriman M, Sullivan JE et al (2014) KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response. Neurology 82(4):368–370
Ohtahara S, Yamatogi Y, Ohtsuka Y (2011) Vitamin B(6) treatment of intractable seizures. Brain Dev 33(9):783–789
Pan Z, Kao T, Horvath Z et al (2006) A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon. J Neurosci 26(10):2599–2613
Shin EJ, Jeong JH, Chung YH et al (2011) Role of oxidative stress in epileptic seizures. Neurochem Int 59(2):122–137
Thériault O, Poulin H, Thomas GR, Friesen AD, Al-Shaqha WA, Chahine M (2014) Pyridoxal-5′-phosphate (MC-1), a vitamin B6 derivative, inhibits expressed P2X receptors. Can J Physiol Pharmacol 92(3):189–196
Wang HS, Kuo MF, Chou ML et al (2005) Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy. Arch Dis Chil 90(5):512–515
Weckhuysen S, Mandelstam S, Suls A et al (2012) KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol 71(1):15–25
Weckhuysen S, Ivanovic V, Hendrickx R et al (2013) Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology 81(19):1697–1703
We would like to thank the child and her family for participating in this study and for consenting to this report. Additional thanks to Emma Wakeling and Frances Cowen for consenting and referring the patient to our centre, respectively. PBM and PTC are supported by Great Ormond Street Hospital Children’s Charity (GOSHCC). This project was funded by grants from the University College London Impact Award and GOSHCC Metabolic Fund. GOSgene is supported by the NIHR BRC at GOSH for Children NHS Foundation Trust and UCL Institute of Child Health. Views expressed are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
Editors and Affiliations
Communicated by: Nicole Wolf, MD PhD
This paper presents a case of KCNQ2 channelopathy showing an apparent response to pyridoxine treatment and indicates that a high plasma to CSF pyridoxal 5′-phosphate ratio is not specific for disorders directly affecting vitamin B6 metabolism.
Compliance with Ethics Guidelines
Conflict of Interest
Emma S. Reid, Hywel Williams, Polona Le Quesne Stabej, Chela James, Louise Ocaka, Chiara Bacchelli, Emma J. Footitt, Stewart Boyd, Maureen A. Cleary, Philippa B. Mills and Peter T. Clayton declare that they have no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.
All authors have read the manuscript and agreed to it being submitted for publication. All individuals listed as authors meet the appropriate authorship criteria, nobody who qualifies for authorship has been omitted from the list, contributors and their funding sources have been properly acknowledged, and all authors and contributors have approved the acknowledgement of their contributions. Emma Reid contributed to data analysis and wrote and submitted the manuscript. Hywel Williams, Polona Le Quesne Stabej, Chela James and Louise Ocaka together prepared the DNA samples for whole-exome sequencing, analysed the data and confirmed the pathogenic mutation. Emma Footitt submitted the initial application for whole-exome sequencing to be carried out. Chiara Bacchelli considered and accepted the application for sequencing. Peter Clayton, Maureen Cleary, Emma Footitt and Emma Reid consulted with the patient and her family regarding the research and the results of the study. Stewart Boyd reviewed all EEGs from the patient. Philippa Mills and Peter Clayton made large contributions to the critical revision of the manuscript. All authors had access to the study data that support this publication.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Data S1: Clinical details of the 23 patients identified who have mutations in KCNQ2 that have been trialled on treatment with pyridoxine or pyridoxal 5′-phosphate. Responses to treatment are stated where available
Data S3: Whole-exome sequencing and touchdown polymerase chain reaction (PCR) conditions
© 2015 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Reid, E.S. et al. (2015). Seizures Due to a KCNQ2 Mutation: Treatment with Vitamin B6 . In: Morava, E., Baumgartner, M., Patterson, M., Rahman, S., Zschocke, J., Peters, V. (eds) JIMD Reports, Volume 27. JIMD Reports, vol 27. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2015_460
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-50408-6
Online ISBN: 978-3-662-50409-3